Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Eoganacht


V.TLT

RE:RE:Good sense of humor

Two words - Ashish Kamat. If our results are very good I don't expect the...

March 1, 2022

V.TLT

DD From Sesen's Annual Report

Disease Overview    Most cancers that form in the bladder are...

March 1, 2022

V.TLT

Sesen Annual Report for SEC

Interesting read while we wait. From page 67 on it deals with the class...

March 1, 2022

V.TLT

Quarterly Newsletter Release

4Q20 was released on Feb 01, 2021 1Q21 was released on Apr 27, 2021 2Q21...

February 24, 2022

V.TLT

Why was TLD1433 preferred over TLD1633?

The answer is in Dr. McFarland's (and Dr. Lilge's) paper describing...

February 21, 2022

V.TLT

RE:RE:New Study of TLD1433 & TLD1633 by Dr. McFarland et al.

Hi Coop - I had forgotten about TLD1633. Back n 2017 they told us it was 15...

February 21, 2022

V.TLT

RE:RE:RE:RE:Upcoming patient data

I think that's the correct interpretation. It's rather deceptive the...

February 19, 2022

V.TLT

RE:RE:RE:Upcoming patient data

So to outdo these results Theralase must maintain a greater than 39% CR rate...

February 19, 2022

V.TLT

New Study of TLD1433 & TLD1633 by Dr. McFarland et al.

McFarland Labs and the Leibniz Insitute of Photonic Technology in Germany...

February 19, 2022

T.PYR

PAWDS

Something tells me we're going to start hearing a lot more about this...

February 18, 2022

V.TLT

Commercialization Timeline Change

In the Sep 2021 Corporate Presentation, on the Phase II Timeline page...

February 17, 2022

V.TLT

Roswell Park's Dr. Gal Shafirstein / Simphotek Project

Back in 2020 Roswell Park's Drs. Gal Shafirstein & Sarah Chamberlain...

February 16, 2022

V.TLT

RE:RE:Well I guess the Thursday push up is on-----seems----

Makes sense. ScienceFirst wrote: Still early in the month to have the...

February 10, 2022

V.TLT

RE:McFarland Laboratory and Modulight

Dr. McFarland has been using Modulight lasers in her lab for years. It's...

February 9, 2022

V.TLT

Repost about Darwyn Kobasa from April 10, 2021

From yesterday's news release: "Darwyn Kobasa, Ph.D., Head, High...

February 8, 2022

V.TLT

RE:RE:This is just wonderful news from the vaccine side---

Awesome indeed! There are 7 human corona viruses. The 4 common ones - ...

February 7, 2022

V.TLT

UTA article on Dr. McFarland's latest research paper

UTA CHEMISTS DISCOVER POTENT ANTI-CANCER AGENT New chemical compound...

February 2, 2022

V.HPQ

RE:Timeline from Corporate Presentation

Eoganacht wrote: Page 21

February 1, 2022

V.HPQ

Timeline from Corporate Presentation

Page 21

February 1, 2022

V.TLT

Dr. Lilge Nominated for Board...

of International Photodynamic Association. It's no surprise that Dr...

February 1, 2022